Johnson & Johnson Medical Device Companies (JJMDC) recently tapped Microsoft to expand its secure and compliant digital surgery ecosystem.
Microsoft Cloud will help JJDMC drive innovation that...
Pfizer and Acuitas Therapeutics recently entered into a development and option agreement under which Pfizer will license Acuitas’ lipid nanoparticle (LNP) technology for up to 10 mRNA vaccine or...
Sanofi and Exscientia recently entered into a research collaboration and license agreement to develop 15 novel small molecule drug candidates across oncology and immunology.
The companies will...
Eli Lilly & Company recently acquired exclusive rights to Entos Pharmaceuticals’ Fusogenix nucleic acid delivery technology to develop nucleic acid products.
The companies will initially...
Moderna recently dosed the first participant in a Phase 1 study of its mRNA vaccine, mRNA-1189, for Epstein-Barr Virus (EBV).
The Eclipse study will enroll nearly 270 participants 18 to 30 years of...
Novartis and Alnylam recently collaborated to leverage proprietary siRNA technology to develop liver-targeted therapy as an alternative to transplantation for patients experiencing liver...
Johnson & Johnson recently announced that its COVID-19 vaccine, Ad26.COV2.S, was 85 percent effective against coronavirus-related hospitalization in a Phase 3b study.
The South African Medical...
FDA recently granted emergency use authorization to Roche’s COVID-19 At-Home Test for children aged 14 years and older and by an adult for children aged two to 13 years.
The COVID-19 At-Home...
Hackensack Meridian Health recently announced its support of the clinical development of a highly-differentiated immuno-oncology platform from Alloplex Biotherapeutics.
This investment is...
Bristol Myers Squibb and clinical-stage biopharmaceutical company Immatics recently entered into a license, development, and commercialization agreement for the bispecific T-cell candidate,...
Kite, a Gilead Company, recently announced positive primary results from a Phase 2 study of Yescarta in patients with high-risk large B-cell lymphoma (LBCL).
The global ZUMA-12 study enrolled 42...
Johnson & Johnson recently announced longer-term results from the Phase 1b/2 study evaluating the safety and efficacy of its T-cell (CAR-T) therapy for patients with relapsed or refractory multiple...
Roche recently launched the AVENIO Edge System to advance next-generation sequencing (NGS) technologies.
Researchers can use the pre-analytical program for sequencing library preparation, target...
Johnson & Johnson recently announced preliminary results from an independent study, which showed that a booster shot of its COVID-19 vaccine increased both antibody and T-cell responses.
In the...
AstraZeneca recently entered into a global development and commercialization agreement with Ionis Pharmaceuticals for transthyretin amyloidosis medication, eplontersen.
Eplontersen is a...
Roche and TIB Molbiol recently added three additional research use only test kits to detect mutations present in the Omicron COVID-19 variant.
The three test kits, VirSNip SARS Spike ins214EPE,...
GSK recently launched an international, multi-year initiative to advance innovation and address key needs in the multiple myeloma community.
The project, Target the Future, will provide education on...
Moderna recently dosed the first participant in the Phase 2/3 study of its mRNA respiratory syncytial virus (RSV) vaccine candidate.
mRNA-1345 is an RSV vaccine for a prefusion F glycoprotein,...
Pfizer and BioNTech recently announced that their COVID-19 vaccine, BNT162b2, was 100 percent effective in adolescents 12 through 15 years of age in a longer-term analysis.
Researchers also...
